We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$109M
Cap. Flow %
10.24%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 65.67%
2 Miscellaneous 21.76%
3 Technology 8.21%
4 Consumer Discretionary 1.63%
5 Industrials 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
76
CALL
Syndax Pharmaceuticals
SNDX
$1.59B
$1.48M 0.14%
+100,000
New +$1.52M
VKTX icon
77
Viking Therapeutics
VKTX
$3.42B
$1.48M 0.14%
205,000
-385,000
-65% -$2.56M
NBSE
78
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.32M 0.12%
+7,500
New +$1.26M
IMUX icon
79
Immunic
IMUX
$139M
$1.21M 0.11%
+10,000
New +$1.02M
ISEE
80
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.02M 0.1%
200,000
+76,576
+62% +$319K
BLU
81
DELISTED
BELLUS Health Inc.
BLU
$1.01M 0.09%
+97,805
New +$991K
NEOS
82
DELISTED
Neos Therapeutics, Inc
NEOS
$651K 0.06%
950,311
-1,559,157
-62% -$1.24M
CAMT icon
83
Camtek
CAMT
$6.71B
$468K 0.04%
+37,184
New +$423K
TCRR
84
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$461K 0.04%
+30,000
New +$346K
CLRB icon
85
Cellectar Biosciences
CLRB
$23M
$112K 0.01%
292
– –
OTLKW
86
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$33K ﹤0.01%
129,500
– –
ACAD icon
87
Acadia Pharmaceuticals
ACAD
$4.71B
– –
-157,000
Closed -$6.63M
ALDX icon
88
Aldeyra Therapeutics
ALDX
$83.9M
– –
-1,069,089
Closed -$2.64M
APLT
89
DELISTED
Applied Therapeutics
APLT
– –
-67,967
Closed -$2.22M
ARVN icon
90
Arvinas
ARVN
$541M
– –
-145,781
Closed -$5.88M
AUDC icon
91
AudioCodes
AUDC
$243M
– –
-206,619
Closed -$4.94M
BEAM icon
92
Beam Therapeutics
BEAM
$2.55B
– –
-264,681
Closed -$4.76M
BPMC
93
DELISTED
Blueprint Medicines
BPMC
– –
-109,500
Closed -$6.4M
CRM icon
94
Salesforce
CRM
$202B
– –
-35,529
Closed -$5.12M
CYCN
95
DELISTED
Cyclerion Therapeutics
CYCN
– –
-6,249
Closed -$331K
DTIL icon
96
Precision BioSciences
DTIL
$177M
– –
-4,912
Closed -$889K
EOLS icon
97
Evolus
EOLS
$520M
– –
-550,000
Closed -$2.28M
IWM icon
98
PUT
iShares Russell 2000 ETF
IWM
$77.2B
– –
-900,000
Closed -$103M
MIST icon
99
Milestone Pharmaceuticals
MIST
$113M
– –
-67,992
Closed -$125K
NERV icon
100
Minerva Neurosciences
NERV
$170M
– –
-21,045
Closed -$1.01M
1 2 3
4
5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $109M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 68% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.